Michael R. Duff

Michael R. Duff

Auto-generated profile, based on publicly available information

Michael R. Duff

Department of Biochemistry & Cellular and Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2020 in The Journal of Biochemistry
Verified
Journal Article
Closed access
MDMichael R Duff
Michael R Duff
JRJasmina S Redzic
Jasmina S Redzic
LRLucas P Ryan
Lucas P Ryan
NPNatasia Paukovich
Natasia Paukovich
RZRui Zhao
Rui Zhao
EEElan Eisenmesser
Elan Eisenmesser
Biliverdin reductase B (BLVRB) family members are general flavin reductases critical in maintaining cellular redox with recent findings revealing that BLVRB alone can dictate cellular fate. However, as opposed to most enzymes, the BLVRB family remains enigmatic with an evolutionarily changing active site and unknown structural and functional consequences. Here, we applied a multi-faceted approach that combines X-ray crystallography, NMR and kinetics methods to elucidate the structural and functional basis of the evolutionarily changing BLVRB active site. Using a panel of three BLVRB isoforms (human, lemur and hyrax) and multiple human BLVRB mutants, our studies reveal a novel evolutionary mechanism where coenzyme ‘clamps’ formed by arginine side chains at two co-evolving positions within the active site serve to slow coenzyme release (Positions 14 and 78). We find that coenzyme release is further slowed by the weaker binding substrate, resulting in relatively slow turnover numbers. However, different BLVRB active sites imposed by either evolution or mutagenesis exhibit a surprising inverse relationship between coenzyme release and substrate turnover that is independent of the faster chemical step of hydride transfer also measured here. Collectively, our studies have elucidated the role of the evolutionarily changing BLVRB active site that serves to modulate coenzyme release and has revealed that coenzyme release is coupled to substrate turnover.

28 July 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MDMichael R. Duff
Michael R. Duff
SGScott A. Gabel
Scott A. Gabel
LPLars C. Pedersen
Lars C. Pedersen
EDEugene F. DeRose
Eugene F. DeRose
JKJuno M. Krahn
Juno M. Krahn
Robert LondonRobert London
Robert London

1 February 2021 in Protein Science
Verified
Journal Article
Open access
PDF file
GFGabriel J. Fuente‐Gómez
Gabriel J. Fuente‐Gómez
CKCreighton L. Kellum
Creighton L. Kellum
AMAlexis C. Miranda
Alexis C. Miranda
MDMichael R. Duff
Michael R. Duff
EHElizabeth E. Howell
Elizabeth E. Howell
R67 dihydrofolate reductase (R67 DHFR) is a plasmid-encoded enzyme that confers resistance to the antibacterial drug trimethoprim. R67 DHFR is a tetramer with a single active site that is unusual as both cofactor and substrate are recognized by symmetry-related residues. Such promiscuity has limited our previous efforts to differentiate ligand binding by NMR. To address this problem, we incorporated fluorine at positions 4, 5, 6, or 7 of the indole rings of tryptophans 38 and 45 and characterized the spectra to determine which probe was optimal for studying ligand binding. Two resonances were observed for all apo proteins. Unexpectedly, the W45 resonance appeared broad, and truncation of the disordered N-termini resulted in the appearance of one sharp W45 resonance. These results are consistent with interaction of the N-terminus with W45. Binding of the cofactor broadened W38 for all fluorine probes, whereas substrate, dihydrofolate, binding resulted in the appearance of three new resonances for 4- and 5-fluoroindole labeled protein and severe line broadening for 6- and 7-fluoroindole R67 DHFR. W45 became slightly broader upon ligand binding. With only two peaks in the F-19 NMR spectra, our data were able to differentiate cofactor and substrate binding to the single, symmetric active site of R67 DHFR and yield binding affinities.

24 June 2020 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
DNDeepika Nambiar
Deepika Nambiar
OSOjaswini Sharma
Ojaswini Sharma
MDMichael R. Duff
Michael R. Duff
EHElizabeth E. Howell
Elizabeth E. Howell

2 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RARupesh Agarwal
Rupesh Agarwal
PPPawat Pattarawat
Pawat Pattarawat
MDMichael R. Duff
Michael R. Duff
HWHwa-Chain Robert Wang
Hwa-Chain Robert Wang
JBJerome Baudry
Jerome Baudry
JSJeremy Smith
Jeremy Smith
Histone deacetylases (HDACs) are important cancer drug targets. Existing FDA-approved drugs target the catalytic pocket of HDACs, which is conserved across subfamilies (classes) of HDAC. However, engineering specificity is an important goal. Herein, we use molecular modeling approaches to identify and target potential novel pockets specific to Class IIA HDAC-HDAC4 at the interface between HDAC4 and the transcriptional corepressor component protein NCoR. These pockets were screened using an ensemble docking approach combined with consensus scoring to identify compounds with a different binding mechanism than the currently known HDAC modulators. Binding was compared in experimental assays between HDAC4 and HDAC3, which belong to a different family of HDACs. HDAC4 was significantly inhibited by compound 88402 but not HDAC3. Two other compounds (67436 and 134199) had IC50 values in the low micromolar range for both HDACs, which is comparable to the known inhibitor of HDAC4, SAHA (Vorinostat). However, both of these compounds were significantly weaker inhibitors of HDAC3 than SAHA and thus more selective, albeit to a limited extent. Five compounds exhibited activity on human breast carcinoma and/or urothelial carcinoma cell lines. The present result suggests potential mechanistic and chemical approaches for developing selective HDAC4 modulators.